Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
The antibody was designed and developed at Abzena’s Cambridge, UK,
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Subscribe To Our Newsletter & Stay Updated